Work

Corrigendum to ‘MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC’ [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450]

Year: 2024

Type: erratum

Abstract: The published version of this article contained an error in Fig. 4C, which does not affect the conclusions of the research. Using Proofig AI following publication, the authors found that the same image for p-EGFR was inadvertently included in Figs. 4A and 4C.

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2024.12.004

Authors: Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Ayako Nakashoji, Hideko Isozaki, Mototsugu Shimokawa, Chie Kikutake, Mikita Suyama, Asato Hashinokuchi, Kazuki Takada, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Tetsuya Mitsudomi, Aaron N. Hata, Donald Kufe

Institutions: Harvard University, Dana-Farber Cancer Institute, Massachusetts General Hospital, Yamaguchi University, Kyushu University, Medical Institute of Bioregulation, Kyushu University, Saiseikai Fukuoka General Hospital, Kindai University Hospital, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,000

OpenAlex ID: W4405542603

Cites:

Cited by: 2

Related to: 10